Book contents
- Handbook of Drugs in Intensive Care
- Handbook of Drugs in Intensive Care
- Copyright page
- Dedication
- Contents
- Introduction
- How to Use This Book
- Common Abbreviations
- Acknowledgements
- Drugs: An A–Z Guide
- Chapter A
- Chapter B
- Chapter C
- Chapter D
- Chapter E
- Chapter F
- Chapter G
- Chapter H
- Chapter I
- Chapter K
- Chapter L
- Chapter M
- Chapter N
- Chapter O
- Chapter P
- Chapter Q
- Chapter R
- Chapter S
- Chapter T
- Chapter V
- Chapter Z
- Short Notes
- Appendices
- Drug Index
Chapter R
from Drugs: An A–Z Guide
- Handbook of Drugs in Intensive Care
- Handbook of Drugs in Intensive Care
- Copyright page
- Dedication
- Contents
- Introduction
- How to Use This Book
- Common Abbreviations
- Acknowledgements
- Drugs: An A–Z Guide
- Chapter A
- Chapter B
- Chapter C
- Chapter D
- Chapter E
- Chapter F
- Chapter G
- Chapter H
- Chapter I
- Chapter K
- Chapter L
- Chapter M
- Chapter N
- Chapter O
- Chapter P
- Chapter Q
- Chapter R
- Chapter S
- Chapter T
- Chapter V
- Chapter Z
- Short Notes
- Appendices
- Drug Index
Summary
Ramipril is an ACE-I; ACE-Is have a beneficial role in all grades of heart failure, usually combined with a beta blocker and diuretics. Potassium-sparing diuretics (e.g. spironolactone) should be discontinued before starting an ACE-I because of the risk of hyperkalaemia. However, low-dose spironolactone may also be beneficial in severe heart failure, and, when used together with an ACE-I, serum potassium needs to be monitored closely.
- Type
- Chapter
- Information
- Handbook of Drugs in Intensive CareAn A-Z Guide, pp. 267 - 277Publisher: Cambridge University PressPrint publication year: 2025